ArticleFrontiers in oncology2025
Development and validation of a predictive model for lymph node metastases in peripheral non-small cell lung cancer with a tumor diameter ≤ 2.0 cm and a consolidation-to-tumor ratio > 0.5.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mediastinal lymph node metastasis pattern of subsolid non-small cell lung cancer.Journal of thoracic disease · 2026Article
- Mediastinal Nodal Evaluation May Be Safely Omitted in Select Patients With Ground Glass-Dominant Lung Adenocarcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Precisely predicting lymph node metastasis (LNM) status is critical for the treatment of early non-small5-cell lung cancer (NSCLC). In this study, we developed a LNM prediction tool for peripheral NSCLC with a tumor diameter ≤ 2.0 cm and consolidation-to-tumor ratio (CTR) > 0.5 to identify patients where segmentectomy could be applied. Methods: Clinical characteristics were retrospectively collected from 435 patients with NSCLC. Logistic regression analysis of the clinical characteristics of this development cohort was used to estimate independent LNM predictors. A prediction model was then developed and externally validated using a validation cohort at another institution. Results: Four independent predictors (tumor size, CTR, pleural indentation, and carcinoembryonic antigen (CEA) values) were identified and entered into the model. The model showed good calibration (Hosmer-Lemeshow (HL) P value = 0.680) with an area under the receiver operating characteristic curve (AUC) = 0.890 (95% confidence interval (CI): 0.808-0.972) in the validation cohort. Conclusions: We developed and validated a novel and effective model that predicted the probability of LNM for individual patients with peripheral NSCLC who had a tumor diameter ≤ 2.0 cm and CTR > 0.5. This model could help clinicians make individualized clinical decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.